Chronic Graft-versus-Host Disease (cGvHD) is a potentially lethal disorder. A variety of second line immunosuppressive agents have been investigated but no optimal treatment has emerged. There is therefore a need for novel treatment strategies. Mesenchymal stromal cells (MSC) exhibit immunomodulatory properties and a recent pilot study suggests a response rate of 70% in steroid- refractory patients. In the present randomized study the efficacy and safety of MSC treatment will be further studied in patients with cGvHD.

Inclusion Criteria:

• Newly diagnosed cGvHD
• Informed consent obtained from patient and donor.
• Any patient who has undergone allogeneic stem cell transplantation with c GvHD.
• Have not received additional agent for cGVHD within 3 months.
• Expected life is more than 90 days.
• Adequate pulmonary function with no evidence of chronic obstructive or severe restrictive pulmonary disease.
• Adequate cardiac function with no evidence of uncontrolled high blood pressure,congestive heart failure, angina pectoris, acute myocardial infarction within 6 months prior to the process.

Exclusion Criteria:

• Invasive fungal disease.
• Active cytomegalovirus (CMV)/Epstein-Barr virus(EBV)/varicella disease).
• Patient is with a history of hypersensitivity to bovine products.
• Relapsed malignancy.